Antibody-induced blockade of PD-L1 has resulted in durable tumor regression and prolonged disease stabilization in patients with advanced cancers, including NSCLC, melanoma, and renal-cell cancer [11]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.